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1. Introduction 
 
Protozoan carbonic anhydrases (CAs, EC 4.2.1.1) such as those from Trypanosoma cruzi, 1-3 
Leishmania donovani chagasi,1,4,5 and Plasmodium falciparum,4,6 started to be investigated in recent 
years as potential drug targets for finding agents enzymes that interfere with the growth and 
proliferation of the parasites which provoke widespread diseases all over the world.2-11 T. cruzi 
encodes for an α-class 7,8 CA (TcCA), which has recently been cloned, characterized and investigated 
for its inhibition, being shown to be a promising new target in the fight against Chagas disease, 
provoked after infection with this protozoan species.1-3 Indeed, both sulfonamide, thiol or 
hydroxamate CA inhibitors (CAIs)7-9 were shown to effectively inhibit in vitro this enzyme, and in 
some cases, also to interfere with the growth of some forms of the parasite in vivo, which may lead 
to the discovery of potential drugs devoid of the drug resistance problems encountered by the few 
clinically used compounds available so far for the treatment of Chagas disease.1-3  
However, in contrast to the CAIs, which were extensively investigated for their interaction with 
various protozoan CAs. Such as those from the malaria parasite, Leishmania spp., and T cruzi,1 the 
CA activators (CAAs)10-12 have been much less investigated at the present time. For the mammalian 
CA isoforms, also belonging to the α-CA genetic family,13-16 similar to TcCA, it has been shown that 
such compounds participate to the CA catalytic cycle, which is shown schematically in Equations 1 
and 2 (where ‘E’ denotes enzyme): 
     H2O 
EZn2+OH- + CO2 ⇔ EZn2+HCO3- ⇔ EZn2+-OH2  +  HCO3-    (1) 
EZn2+-OH2 ⇔ EZn2+OH-  +  H+                                                    (2) 
The first step (Equation 1) involves a nucleophilic attack of a zinc-bound hydroxide species 
of the enzyme on the CO2 substrate, that is bound in a hydrophobic pocket nearby. in an optimal 
orientation for the hydration reaction to bicarbonate.11,16 Bicarbonate formed in the hydration reaction 
is then replaced by an incoming water molecule to generate the catalytically acidic form of the 
enzyme, EZn2+OH2 (Equation 1), whereas bicarbonate is released into the solution. For the 
regeneration of the zinc hydroxide species, a proton transfer reaction occurs from the Zn(II)-bound 
water molecule to the external reaction medium (Equation 2), which is the rate-determining step of 
the entire catalytic cycle.10 
EZn2+-OH2  + A⇔[EZn2+-OH2 - A] ⇔[EZn2+OH- - AH+]⇔ EZn2+OH- + AH+     (3) 
    enzyme - activator complexes 
In the presence of activators (A in Equation 3), formation of enzyme-activator complexes 
occurs, in which the proton transfer step becomes intramolecular and thus, more efficient than the 
corresponding intermolecular process shown schematically in Eq. 2.10,16 The CA activation 
mechanism was demonstrated by extensive kinetic and X-ray crystallographic studies on the human 
isoforms hCA I and II.10-16 Based on such studies it has been shown that the activator was bound at 
the entrance to the active site cavity, region from which it can interfere with the proton transfer 
reactions between the active site and the reaction medium. In fact, most of the activators studies so 
far belong to the amino and/or amino acid derivatives, and possess moieties with an appropriate pKa 
(generally in the range of 6-8) for an efficient proton shuttling processes between the active site and 
the environment.10-17  
CAAs were only recently shown to possess the potential of acting as pharmacological agents 
for the therapy of memory disorder and cognition impairment.16 However, unlike CAIs, which are 
clinically used as diuretics,18 antiglaucoma drugs,19 antiobesity,20 antitumor,21 anti-neuropathic 
pain,22 or anti-arthritis agents,23 there are no clinically approved CAAs. The natural and non-natural 
amino acids and amines of type 1-24 are among the most investigated CAAs, and they were also 
evaluated in the present study for their interaction with the protozoan enzyme TcCA (Fig. 1).  
 
2. Experimental 
 
2.1. Chemistry. Amino acids and amines 1-24 were commercially available, highest purity reagents 
from Sigma-Aldrich, Milan, Italy. TcCA was a recombinant protein produced as reported earlier by 
our group.2 
 
2.2. CA enzyme activation assay 
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to assay 
the catalytic activity of various CA isozymes for CO2 hydration reaction.17 Phenol red (at a 
concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, 
with 10 mM Hepes (pH 7.5) as buffer, 0.1 M Na2SO4 (for maintaining constant ionic strength), 
following the CA-catalyzed CO2 hydration reaction for a period of 10 s at 25 ◦C. The CO2 
concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters and 
activation constants. For each activator at least six traces of the initial 5-10% of the reaction have 
been used for determining the initial velocity. The uncatalyzed rates were determined in the same 
manner and subtracted from the total observed rates. Stock solutions of activators (10 mM) were 
prepared in distilled-deionized water and dilutions up to 1 nM were done thereafter with the assay 
buffer. Activator and enzyme solutions were pre-incubated together for 15 min (standard assay at 
room temperature) prior to assay, in order to allow for the formation of the E–A complex. The 
activation constant (KA), defined similarly with the inhibition constant KI, can be obtained by 
considering the classical Michaelis–Menten equation (equation 4), which has been fitted by non-
linear least squares by using PRISM 3: 
   v =vmax/{1+(KM/[S])(1+[A]f/KA)}                                              (4) 
where [A]f is the free concentration of activator. 
Working at substrate concentrations considerably lower than KM ([S] <<KM), and considering that 
[A]f can be represented in the form of the total concentration of the enzyme ([E]t)and activator ([A]t), 
the obtained competitive steady-state equation for determining the activation constant is given by 
equation 5: 
          v=v0.KA/{KA+([A]t-0.5{([A]t+[E]t+KA)-([A]t+[E]t+KA)2-4[A]t.[E]t)1/2}}     (5) 
where v0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of 
activator.10,24,25 
 
3. Results and Discussion 
 
 
 
 
Table 1: Activation of human carbonic anhydrase (hCA) isozymes I, II, and TcCA with L-Trp, at 
25°C, for the CO2 hydration reaction.17  
Isozyme  kcat*  KM*  (kcat)L-Trp**  KA*** (µM) 
   (s-1)  (mM)  (s-1)   L-Trp 
hCA Ia   2.0x105 4.0  3.4x105  44.0 
hCA IIa  1.4x106 9.3  4.9x106  27.0 
TcCAb   1.2×106 8.1  7.8×106  2.54 
_______________________________________________________________________________ 
* Observed catalytic rate without activator. KM values in the presence and the absence of activators were the 
same for the various CAs (data not shown). 
** Observed catalytic rate in the presence of 10 µM activator. 
*** The activation constant (KA) for each enzyme was obtained by fitting the observed catalytic 
enhancements as a function of the activator concentration.13 Mean from at least three determinations by a 
stopped-flow, CO2 hydrase method.30 Standard errors were in the range of 5-10 % of the reported values 
(data not shown). 
aHuman recombinant isozymes, from ref.13; b Protozoan recombinant enzyme, this work. 
 The structure-activity relationship (SAR) for the activation of TcCA with compounds 1-24, 
can be delineated considering the data shown in Table 2, where the activation data of the human 
isoforms hCA I and II are also presented for comparison. 
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Fig. 1: Amino acids 1-24 investigated as TcCA activators. 
 
 
Table 2: Activation constants of hCA I, hCA II and the protozoan enzyme TcCA with amino acids 
and amines 1 – 24. Data for hCA I and II are from ref.16 
No. Compound     KA (µM)*  
     hCA Ia  hCA IIa LdcCAb TcCAc 
1 L-His    0.03  10.9  8.21  11.3 
2 D-His    0.09  43  4.13  7.54 
3 L-Phe    0.07  0.013  9.16  12.1 
4 D-Phe    86  0.035  3.95  6.39 
5 L-DOPA   3.1  11.4  1.64  0.83 
6 D-DOPA   4.9  7.8  5.47  0.38 
7 L-Trp    44  27  4.02  2.54 
8 D-Trp    41  12  6.18  1.79 
9 L-Tyr    0.02  0.011  8.05  4.92 
10 D-Tyr    0.04  0.013  1.27  2.80 
11 4-H2N-L-Phe   0.24  0.15  15.9  0.75 
12 Histamine   2.1  125  0.74  2.73 
13 Dopamine   13.5  9.2  0.81  >100 
14 Serotonin   45  50  0.62  1.98 
15 2-Pyridyl-methylamine 26  34  0.23  >100 
16 2-(2-Aminoethyl)pyridine 13  15  0.012  >100 
17 1-(2-Aminoethyl)-piperazine 7.4  2.3  0.009  >100 
18 4-(2-Aminoethyl)-morpholine 0.14  0.19  0.94  6.95 
19 L-Adrenaline   0.09  96  4.89  >100 
20 L-Asn    11.3  >100  4.76  >100 
21 L-Asp    5.20  >100  0.30  18.7 
22 L-Glu    6.43  >100  12.9  >100 
23 D-Glu    10.7  >100  0.082  >100 
24 L-Gln    >100  >50  2.51  2.85 
* Mean from three determinations by a stopped-flow, CO2 hydrase method.17 Standard 
errors were in the range of 5-10 % of the reported values (data not shown). 
a Human recombinant isozymes, stopped flow CO2 hydrase assay method;16b 
b Protozoan recombinant enzyme, from ref. 25b 
 cThis work. 
 
 
 
and of 13-15 µM for the human CAs. Thus, this compound may be used as a pharmacologic tool to 
explore the role that LdcCA might play in the life cycle of this protozoan and whether CA activation 
is important for the infection or host colonization by Leishmania, in diverse phases of the pathogen’s 
life cycle. 
 
4. Conclusions 
The first activation study of a protozoan  
 
Because activators have not been identified for protozoan CAs, this study should be important for 
understanding the role that this enzyme has in the life cycle of Leishmania, particularly considering 
the fact that many of the activators identified are autacoids present in rather high concentrations in 
different tissues of the host mammals that are infected by these parasites. 
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